產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-MARCH9抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-MARCH9抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-MARCH9
Cat. Number:
Anti-MARCH9抗體KL-9343R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Ubiquitination is an important mechanism through which three classes of enzymes act in concert to target short-lived or abnormal proteins for destruction. The three classes of enzymes involved in ubiquitination are the ubiquitin-activating enzymes (E1s), the ubiquitin-conjugating enzymes (E2s) and the ubiquitin-protein ligases (E3s).Anti-MARCH9抗體 MARCH9 (membrane-associated ring finger (C3HC4) 9), also known as RNF179, is a 346 amino acid multi-pass membrane protein that localizes to the golgi apparatus and contains one RING-CH-type zinc finger. Expressed ubiquitously, MARCH9 exists as a homodimer and functions as an E3 ubiquitin-protein ligase that accepts a ubiquitin residue from an E2 ubiquitin-conjugating enzyme and is thought to promote the degradation of target proteins, such as CD4 and MHC-I. Multiple isoforms of MARCH9 exist due to alternative splicing events.
Also known as:
E3 ubiquitin protein ligase MARCH9; Anti-MARCH9抗體MARCH IX; Membrane associated RING CH protein IX; membrane associated ring finger (C3HC4) 9; Membrane associated RING finger protein 9; RING finger protein 179; RNF179; MARH9_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated Anti-MARCH9抗體synthetic peptide derived from human MARCH9.
●
Predicted Molecular Weight: 38kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-F=1:100-500 Flow-Cyt=1:20-500 IF=1:50-200
Not yet tested in other applications. Anti-MARCH9抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-MARCH9抗體
Optimal working dilutions must be determined by the end user.
